Epidemiology and molecular characterization of co-circulating influenza A/H3N2 virus variants in children: Houston, Texas, 1997-8

Epidemiology and Infection

Volumn 130, Issue 3, 2003, Pages 521-531

  O'Donnell, F T ^a   Munoz, F M ^b   Atmar, R L ^b   Hwang, L Y ^a   Demmler, G J ^b,c   Glezen, W P ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Texas Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT;

ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL FEATURE; DEMOGRAPHY; DISEASE SEVERITY; HOUSEHOLD; HUMAN; INFANT; INFLUENZA VIRUS A; NONHUMAN; NOSE; NUCLEOTIDE SEQUENCE; RESPIRATORY TRACT INFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNITED STATES; VIRUS CLASSIFICATION; VIRUS ISOLATION; VIRUS STRAIN;

EID: 0038680612     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0950268803008276     Document Type: Article

References (42)

1. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281: 61-6.
2. Barker WH. Excess pneumonia- and influenza-associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health 1986; 76: 761-5.
3. Glezen WP, Paredes A, Taber LH. Influenza in children: relationship to other respiratory agents. JAMA 1980; 243: 1345-9.
4. Sullivan KM, Monto AS, Longini IM. Estimates of the US health impact of influenza. Am J Public Health 1993; 83: 1712-6.
5. Ohmit SE, Monto AS. Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol 1995; 24: 1240-8.
6. Monto AS. Prospects for pandemic influenza control with currently available vaccines and antivirals. J Infect Dis 1997; 176 (Suppl 1): S32-7.
7. Perrotta DM, Decker M, Glezen WP. Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza. Am J Epidemiol 1985; 122: 468-76.
8. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000; 283: 499-505.
9. Crosby AW. America's forgotten pandemic: the influenza of 1918. New York: Cambridge University Press, 1989: 56-69.
10. Shortridge KF. The next virus pandemic. Lancet 1995; 346: 1210-2.
11. Hampton AW. Surveillance for pandemic influenza. J Infect Dis 1997; 176 (Suppl 1): S8-13.
12. Schoenbaum SC, Coleman MT, Dowdle WR, Mostow SR. Epidemiology of influenza in the elderly: evidence of virus recycling. Am J Epidemiol 1976; 103: 166-73.
13. Anonymous, Update: isolation of avian influenza A (H5N1) viruses from humans - Hong Kong, 1997-98. MMWR 1998; 46: 1245-6.
14. Cox NJ, Bender CA. The molecular epidemiology of influenza viruses. Seminars Virol 1995; 6: 359-70.
15. Shortridge KF, Stuart-Harris CH. An influenza epicenter. Lancet 1982; ii: 812-3.
16. Anonymous, Update: influenza activity - United States, 1997-98 season. MMWR 1998; 47: 196-200.
17. Noyola DE, Clark B, O'Donnell FT, Atmar RL, Greer J, Demmler GJ. Comparison of new neuraminidase detection assay with an enzyme immunoassay, immunofluorescence, and culture for rapid detection of influenza A and B viruses in nasal wash specimens. J Clin Microbiol 2000; 38: 1161-5.
18. Couch RB, Kasel JA. Influenza. In: Lennette EH, Lennette DA, Lennette ET, eds. Diagnostic procedures for viral, rickettsial, and chlamydial infections, 7th ed. Washington, D.C.: American Public Health Association, 1995: 431-46.
19. Atmar RL, Baxter BD. Typing and subtyping clinical isolates of influenza virus using reverse transcriptase-polymerase chain reaction. Clin Diagn Virol 1996; 7: 668-74.
20. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheimvan Dillen PME, van der Noord J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28: 495-503.
21. Atmar RL, Baxter BD, Dominguez EA, Taber, LH. Comparison of reverse transcription-PCR with tissue culture and other rapid diagnostic assays for detection of type A influenza virus. J Clin Microbiol 1996; 34: 2604-6.
22. Peacock AC, Dingman CW. Molecular weight estimation and separation of ribonucleic acid by electrophoresis in agarose-acrylamide composite gels. Biochemistry 1968; 7: 668-74.
23. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79: 340-9.
24. Glezen WP, Keitel WA, Taber LH, Piedra PA, Clover RD, Couch RB. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1 : comparison to age-specific infection rates, 1978-1989. Am J Epidemiol 1991; 133: 296-304.
25. Chakraverty P. Antigenic relationship between influenza viruses. Bull WHO 1971; 45: 755-66.
26. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000; 136: 168-75.
27. Chan PKS, Sung RYT, Fung KSC, et al. Epidemiology of respiratory syncytial virus infection among paediatric patients in Hong Kong: seasonality and disease impact. Epidemiol Infect 1999; 123: 257-62.
28. Saijo M, Terunuma H, Mizuta K, et al. Respiratory syncytial virus infection in children with acute respiratory infections in Zambia. Epidemiol Infect 1998; 121: 397-400.
29. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffen MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. New Engl J Med 2000; 342: 225-31.
30. Munoz FM, Galasso GJ, Gwalty JM, et al. Current research on influenza and respiratory viruses: II international symposium. Antiviral Res 2000; 46: 91-124.
31. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46 (RR-8): 1-2.
32. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. New Engl J Med 1995; 333: 889-93.
33. Prevention and control of influenza: part I, vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1994; 43 (RR-9): 1-13.
34. Colquboun AJ, Nicholson KG, Botha JL, Raymond NT. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 1997; 119: 335-41.
35. Poehling KA, Sperof T, Dittus R, Griffin MR, Hickson GB, Edwards KM. Predictors of influenza virus vaccination status in hospitalized children. Pediatrics 2001; 108: e99.
36. Ellis JS, Sadler CJ, Laidler P, Rebelode Andrade H, Zambon MC. Analysis of influenza A H3N2 strains isolated in England during 1995-1996 using polymerase chain reaction restriction. J Med Virol 1997; 51: 234-41.
37. Zhou S. A practical approach to genetic screening for influenza virus variants. J Clin Microbiol 1997; 35: 2623-7.
38. Ellis JS, Zambon MC. Molecular analysis of an outbreak of influenza in the United Kingdom. Eur J Epidemiol 1997; 13: 369-72.
39. Offringa DP, Tyson-Medlock V, Ye Z, Levandowski RA. A comprehensive systematic approach to identification of influenza A virus genotype using RT-PCR and RFLP. J Virol Methods 2000; 88: 15-24.
40. Coiras MT, Aguilar JC, Galiano M, et al. Rapid molecular analysis of the haemagglutinin gene of human influenza a H3N2 viruses isolated in Spain from 1996 to 2000. Arch Virol 2001; 146: 2133-47.
41. Patriarca PA, Cox NJ. Influenza pandemic preparedness plan for the United States. J Infect Dis 1997; 176 (Suppl 1): S4-7.
42. US Preventive Services Task Force. Guide to clinical preventive services. Baltimore: Williams & Wilkins, 1989: 363-8.